UnitedHealth's stock plunged after government signals crackdown on Medicare Advantage fraud
By Jaimy Lee
The shares have tumbled 19% over the past five days over worries about stricter auditing of 'upcoding' and new Medicare for All proposals. Other health insurance stocks also slide.
UnitedHealth Group's stock is down this week, in part due to concerns about a government proposal to crack down on fraud in the Medicare Advantage program.
UnitedHealth's stock tumbled again on Thursday amid a tough week in which the government pledged to crack down on Medicare Advantage fraud and lawmakers renewed a call for Medicare for All.
UnitedHealth shares (UNH) closed 5.6% lower on Thursday, alongside a widespread selloff of health-insurance and biopharma stocks. The stock has plunged 19% over the last five days.
The primary concern for the sprawling healthcare conglomerate is the proposal from the Centers for Medicare and Medicaid Services on Monday to implement new rules to prevent fraud within government healthcare programs like Medicare.
This would be "a potentially significant expansion of federal oversight across federally funded health programs," Raymond James analyst Chris Meekins told investors earlier this week.
The most worrisome part of the proposed rule for health insurers that participate in Medicare Advantage is how the government wants to audit diagnosis codes going forward. There are well-documented concerns that insurers engage in "upcoding," the practice of recording patients as sicker than they are so insurers can receive bigger payments from Medicare.
A spokesperson for UnitedHealth declined to comment.
Humana's stock (HUM) has tumbled 15.8% over the last five days, while shares of CVS Health (CVS), which operates Aetna, are down 10.9%.
But there's potentially more at risk for these companies than just the proposed changes to Medicare Advantage.
Meekins believes that the Medicare for All proposals from Sen. Bernie Sanders, an independent from Vermont, and Rep. Hakeem Jeffries, the incoming speaker of the House, are further weakening shares of health insurers and hospitals, in part because the new proposals are more incremental than those that call for wiping the slate clean and starting over with a single-payer system.
Sanders, for example, has suggested that Medicare eligibility could start at age 55 rather than 65, while both lawmakers have suggested adding coverage of routine dental, hearing and vision care to traditional Medicare.
"It appears that investors are pricing in the headline risk now, even though any legislative effect is likely years away," William Blair analyst Ryan Daniels told investors.
-Jaimy Lee
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
11-19-26 1622ET
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular

5 Stocks to Buy After Earnings

The 10 Best Dividend Stocks

7 Undervalued Stocks That Crushed Earnings

This Newly Undervalued Stock Has Plenty of Growth Ahead

